Chemotherapy for ovarian cancer - trials, controversies and funding
1998
Chemotherapy for Ovarian Cancer: Trials and Controversies
Editorial
Author Information
Author(s): RE Hawkins
Primary Institution: Christie CRC Research Centre
Conclusion
Paclitaxel-platinum combinations are likely the best treatment for advanced ovarian cancer, but more data is needed to confirm this.
Supporting Evidence
- Paclitaxel-cisplatin is superior to cyclophosphamide-cisplatin.
- Indirect evidence supports the use of either paclitaxel-cisplatin or paclitaxel-carboplatin.
- Single-agent cisplatin may be as effective as paclitaxel-cisplatin.
Takeaway
Doctors are trying to figure out the best medicine for women with advanced ovarian cancer, and they think a mix of two drugs works best, but they need more tests to be sure.
Potential Biases
Funding issues and bureaucratic delays may affect trial participation and results.
Limitations
The initial trials were small and lacked sufficient data for subgroup analysis.
Want to read the original?
Access the complete publication on the publisher's website